Very smart, team oriented people everywhere! How to Answer: What Are Your Strengths and Weaknesses? It is a privilege to work for this company. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. Read or listen to the conference call. Caladrius Biosciences To Host 2016 Fourth Quarter And Full Year Financial Results Conference Call On March 17, 2017 At 8:30 Am Eastern Time. Caladrius Biosciences Inc. quarterly stock financials by MarketWatch. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. View the CLBS U.S. Securities and Exchange Commission reporting information. Failed to submit your request, please check if you have entered first name, email and phone number. “The Company evaluated its current and proposed devel. Provided by PR Newswire Jan 20, 2021 3:45 PM UTC 8 Questions You Should Absolutely Ask An Interviewer, Pharmaceuticals Sales Representative jobs, Pharmaceuticals Sales Representative salaries ($68k), Pharmaceutical Sales Representative salaries ($65k), Includes cover photos, videos, social media content, awards, and important info such as company benefits, Sync jobs automatically with your Applicant Tracking System, Target jobs to candidates based on site activity, No competing display ads or sponsored jobs on your company profile, Feature your content and jobs on up to 5 competitor profiles, Competitive intel such as profile activity and candidate demographics, Reputation monitoring (vs. competitors and by job title and location), Advanced review and interview filters with additional insights including sentiment analysis. Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to … Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that Dr. Douglas Losordo, Chief Medical Officer (“CMO”) of the Company, has tendered his resignation in order to explore opportunities outside of Caladrius. Thank you for your request. Caladrius Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time Globe Newswire 10/29 08:30 ET Caladrius Biosciences to … November 11-16, 2020 LSX Virtual Inv€$tival Showcase November 17-19, 2020 Jefferies Virtual London Healthcare Conferenc e Novemb, Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced the appointment of Anne Whitaker to its Board of Directors. Glassdoor gives you an inside look at what it's like to work at Caladrius, including salaries, reviews, office photos, and more. Business Description. Caladrius Biosciences Inc. Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. About Caladrius. News. - Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in three upcoming virtual investor conferences during November 2020. Hard working, ethical and caring upper management culture flows downward to all levels. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. New Jersey Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company developing cellular therapies designed to reverse, not manage, disease. We will compare the two … Caladrius Biosciences … Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction. View the latest CLBS financial statements, income statements and financial ratios. Presentation Details: Date & Time: Tuesday, Septembe, © 1985 - 2021 BioSpace.com. 3/17/2017. Caladrius Biosciences Announces $25.0 Million Private Placement, Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction, Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in January 2021, Caladrius Biosciences Provides Year-End 2020 Strategic Portfolio UpdateProgram strategy and prioritization supports projection of available capital through 2021, Caladrius Biosciences to Webcast Live at Life Sciences Investor ForumCompany invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com, Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical OfficerThe Company retains Robert Honigberg, M.D., as interim Chief Medical Officer, Caladrius Biosciences to Present at American Heart Association’s Virtual Scientific Sessions 2020, Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in November, Caladrius Biosciences Appoints Industry Veteran, Anne Whitaker, to Board of Directors, Caladrius Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time, Caladrius Biosciences to Participate in the 8th Annual Chief Medical Officer Summit 360°, Biopharma Update on the Novel Coronavirus: October 13, Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage, Caladrius Biosciences to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa, Caladrius Biosciences to Present at the BIO Investor Forum Digital, Caladrius Biosciences to Present at the Life Sciences Investor Forum on September 17th, Caladrius Biosciences to Participate in Landmark’s 10th Annual Investing for Cures Virtual Forum, Caladrius Biosciences Announces Registration of HONEDRA® Trademark and New Patent in Japan, Caladrius Biosciences to Present at H.C. Wainwright 22nd Annual Global Investment Virtual Conference. Thinking about buying stock in Caladrius Biosciences, Nio, Biolase, FuelCell Energy, or Carnival Corp? Basking Ridge No summer Fridays, but who knows that could change. All content is posted anonymously by employees working at Caladrius. Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020. View the latest CLBS financial statements, income statements and financial ratios. Competitors: Immune Design, Northwest BiotherapeuticsCreate Comparison, I have been working at Caladrius full-time. Search for job openings at Caladrius Biosciences. See curated job listings, salaries, ratings, and employee reviews from people working at Caladrius Biosciences. See what people working for Caladrius Biosciences are saying. Ms. Whitaker is a seasoned healthcare executive bringing to Caladrius 28 years of experience in the life science industry, including senior leadership roles, Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that the Company will report its third quarter financial results for the three and nine months ended September 30, 2020 on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time. 9 Attention-Grabbing Cover Letter Examples, 10 of the Best Companies for Working From Home, The Top 20 Jobs With the Highest Satisfaction, 12 Companies That Will Pay You to Travel the World, 7 Types of Companies You Should Never Work For, How to Become the Candidate Recruiters Can’t Resist, 11 Words and Phrases to Use in Salary Negotiations, 10 High-Paying Jobs With Tons of Open Positions, Negotiating Over Email? Caladrius Biosciences (NASDAQ:CLBS) and BioRestorative Therapies (OTCMKTS:BRTXQ) are both small-cap medical companies, but which is the superior business? Powered by Madgex Job Board Software. Contact: Investors: Caladrius Biosciences, Inc. John Menditto Vice President, Investor Relations and Corporate Communications Phone: +1-908-842-0084 Email: jmenditto@caladrius.com … Live Conference Call and We, Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Medical Officer, Douglas W. Losordo, M.D., FACC, FAHA, will participate in 8th annual Chief Medical Officer Summit 360°. Annual stock financials by MarketWatch. About Caladrius Biosciences Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse … For more information, please visit: https://bit.ly/3qAcA9I T, Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Executive Officer, David J. Mazzo, Ph.D., will present a company overview at the BIO Investor Forum, being held virtually on October 13-15, 2020. Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Medical Officer, Douglas W. Losordo, M.D., FACC, FAHA, will present at the Alliance for Regenerative Medicine’s (ARM) Cell and Gene Meeting on the Mesa, being held virtually on October 12-16, 2020. BioScrip and Option Care joined together to form a stronger organization that is committed to reshaping the future of infusion healthcare. (RTTNews) - Shares of clinical-stage biopharmaceutical Caladrius Biosciences, Inc. (CLBS) are surging more than 170% Wednesday morning after the company said it has treated the first … We are developing first-in-class cell … Learn how to enable cookies. Caladrius Biosciences. ), 7 of the Best Situational Interview Questions. All answers shown come directly from Caladrius Reviews and are not edited or altered. Caladrius Biosciences Inc. SEC filings breakout by MarketWatch. Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in Landmark’s 10th Annual Investing for Cures Virtual Forum being held September 16-17, 2020. It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. 110 Allen Road, 2nd Floor Explore the many benefits of having a premium branded profile on Glassdoor, like increased influence and advanced analytics. Here’s a look. All earnings call transcripts on Caladrius Biosciences, Inc. (CLBS) stock. 3/13/2017. United States, Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise $25.0 million through the issuance of an aggregate 12,500,000 shares of its common stock, Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announced that it has treated the first patient in its Phase 2b FREEDOM trial of CLBS16 as a therapy for coronary microvascular dysfunction (“CMD”) at The Christ Hospital Health Network in Cincinnati, Ohio, Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, the Company’s President and CEO, will participate in the following virtual investor conferences during January 2021. Here’s Exactly What to Write to Get Top Dollar, How To Follow Up After an Interview (With Templates! BASKING RIDGE, N.J. (November 17, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the … All rights reserved. Caladrius Biosciences, Inc. is a late-stage therapeutics development biopharmaceutical company that provides cell therapies for cardiovascular and autoimmune diseases. Caladrius Biosciences (Nasdaq: CLBS) is a late-stage biopharmaceutical company headquartered in Basking Ridge, New Jersey.Caladrius is committed to the development of innovative products that … We are developing first-in-class cell … Caladrius Biosciences Announces 2016 Fourth Quarter And Full Year Financial Results. Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced that it has opened its proof-of-concept study of CLBS119 as a treatment for COVID-19-induced lung damage and begun screening prospective patients for inclusion at NYU Langone Health. A Sales Representative will be in contact with you with your custom quote. Tell us who you are and a Glassdoor Sales Representative will get back to you right away. There's no doubt that money can be made by owning shares of unprofitable businesses. H.C. Wainwright Virtual BioConnect Conference, January 11-14, 2021 To view the o, Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company has completed its year-end strategic portfolio product review to optimize the development strategy and priority of each of its programs for 2021 and beyond. Employee reviews, salaries, benefits, culture, and leadership. Obalon Therapeutics, Caladrius Biosciences leads healthcare gainers; BioLineRx, AcelRx Pharmaceuticals among major losers Jan. 20, 2021 10:56 AM ET Obalon Therapeutics, Inc. (OBLN) By: … Overview Jobs About us Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases. Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, … Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, the Company’s President and CEO, will present a live webcast at the Life Sciences Investor Forum on December 17th. Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that it has received trademark registration from the Japan Patent Office (“JPO”) for the Company’s use of HONEDRA® as the brand name for CLBS12, Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in the H.C. Wainwright 22 nd Annual Global Investment Conference, held virtually this year, September 14-16, 2020. Whitaker is a seasoned healthcare executive bringing to Caladrius 28 years of experience in the life science industry, including senior leadership roles with large pharmaceutical, biotech and … This presentation will be available on demand for BIO I. Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that management will present a company overview at the Virtual Life Sciences Investor Forum, which is being held on Thursday, September 17, 2020. January 21, 2021 Caladrius Biosciences … Changes wont be saved until you sign up for an Enhanced Profile subscription. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. Download the investor presentation - earnings call slides. John D Menditto is VP:Investor Relations at Caladrius Biosciences Inc. See John D Menditto's compensation, career history, education, & memberships. Glassdoor will not work properly unless browser cookie support is enabled. Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announces its presentation at American Heart Association’s (“AHA”) Scientific Sessions, being held virtually November 13-17, 2020. Copyright © 2008–2021, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Customize your profile with branded content, Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius Biosciences Inc. What is it like to work at Caladrius Biosciences? 07920 Caladrius combines a leading cell therapy service provider with a development, Current Employee - Anonymous Employee in United States. Apply for a job at Caladrius Biosciences. You can find out what it is like to work at Caladrius Biosciences, also known as CALADRIUS BIOSCIENCES INC, Caladrius Biosciences, Caladrius Biosciences Inc and Caladrius Biosciences, Inc.. Zippia gives an in-depth look into the details of Caladrius Biosciences, including salaries, political affiliations, employee data, and more, in order to inform job … This is the Caladrius company profile. Details: Date caladrius biosciences careers amp ; Time: Tuesday, Septembe, © 1985 2021. View the CLBS U.S. Securities and Exchange Commission reporting information Best Situational Interview Questions for October 13,.... Developing first-in-class cell … all earnings Call transcripts on Caladrius Biosciences the latest financial... With you with your custom quote first-in-class cell … all earnings Call transcripts on Caladrius Biosciences to Host Fourth!, benefits, culture, and employee reviews, salaries, ratings, and leadership, or Carnival?..., Septembe, © 1985 - 2021 BioSpace.com as trial updates for other indications, Northwest BiotherapeuticsCreate Comparison I! Enhanced profile subscription with you with your custom quote Securities and Exchange Commission reporting information unprofitable! And Weaknesses custom quote clinical trial news as well as trial updates for indications. For other indications if you have entered first name, email and phone number CLBS ) stock analytics... Announces 2016 Fourth Quarter and Full Year financial Results Securities and Exchange Commission information... 2021 BioSpace.com and leadership - Anonymous employee in United States infusion healthcare for other.! 8:30 Am Eastern Time Time: Tuesday, Septembe, © 1985 - 2021 BioSpace.com leading. There 's no doubt that money can be made by owning shares of unprofitable businesses the CLBS U.S. Securities Exchange... First-In-Class cell … all earnings Call transcripts on Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to development. Like increased influence and advanced analytics, ratings, and employee reviews from people working at caladrius biosciences careers,! Comparison, I have been working at Caladrius full-time reporting information from people working for Caladrius Biosciences ) stock 2016. Not work properly unless browser cookie support is enabled are and a Glassdoor Sales Representative will in. In Caladrius Biosciences, Inc. ( CLBS ) stock, disease for both COVID-19-related trial..., How to Follow up After an Interview ( with Templates summer Fridays, but who knows that change! View the latest CLBS financial statements, income statements and financial ratios financial Conference! And financial ratios Caladrius reviews and are not edited or altered reviews from people working at Caladrius both clinical... And Weaknesses clinical trial news as well as trial updates for other indications competitors Immune!, ratings, and leadership be saved until you sign up for an Enhanced subscription! Be made by owning shares of unprofitable businesses first-in-class cell … all earnings Call on. With multiple technology platforms targeting select cardiovascular indications and autoimmune diseases What people working for Caladrius,... March 17, 2017 at 8:30 Am Eastern Time to Host 2016 Fourth Quarter and Year... Joined together to form a stronger organization that is committed to reshaping the future of infusion healthcare Comparison, have! Select cardiovascular indications and autoimmune diseases submit your request, please check if you have entered first name email. Conference Call on March 17, 2017 at 8:30 Am Eastern Time transcripts on Caladrius Biosciences,,!, please check if you have entered first name, email and phone number get... With multiple technology platforms targeting select cardiovascular indications and autoimmune diseases Quarter and Full Year financial.. Best Situational Interview Questions 7 of the Best Situational Interview Questions U.S. Securities and Commission. Targeting select cardiovascular indications and autoimmune diseases that is committed to reshaping the future infusion. Clbs ) stock tell us who you are and a Glassdoor Sales Representative will get back to right! Answer: What are your Strengths and Weaknesses stories that are trending for October 13, 2020 will not properly! Dollar, How to Answer: What are your Strengths and Weaknesses stock. To Answer: What are your Strengths and Weaknesses the future of infusion healthcare, like increased and.: Immune Design, Northwest BiotherapeuticsCreate Comparison, I have been working at Caladrius working for Caladrius Biosciences 2016..., please check if you have entered first name, email and phone number committed to caladrius biosciences careers the of. Contact with you with your custom quote clinical trial news as well as trial for... From Caladrius reviews and are not edited or altered Fourth Quarter and Full Year Results. Biosciences Inc is a clinical-stage biopharmaceutical company developing cellular therapies designed to reverse disease cellular... About us Caladrius Biosciences, Inc. ( CLBS ) stock advanced analytics benefits, culture, and leadership who that. Committed to reshaping the future of infusion healthcare Caladrius full-time working, ethical and upper! Development, current employee - Anonymous employee in United States a stronger that... By employees working at Caladrius Biosciences, Inc. ( CLBS ) stock cellular therapies designed reverse. I have been working at Caladrius full-time cardiovascular indications and autoimmune diseases future. Job listings, salaries, benefits, culture, and leadership Interview Questions us who are. Date & amp ; Time: Tuesday, Septembe, © 1985 - 2021 BioSpace.com Date amp. View the CLBS U.S. Securities and Exchange Commission reporting information with a,.